Hospitalization cost estimates of respiratory syncytial virus and influenza infections in adults in Spain, 2016-2019

被引:0
作者
Haeberer, M. [1 ]
De Aldecoa, A. Lopez-Ibanez [1 ]
Seabroke, S. [2 ]
Agudelo, J. L. Ramirez [2 ]
Mora, L. [2 ]
Sarabia, L. [2 ]
Peerawaranun, P. [2 ]
Meroc, E. [2 ]
Aponte-Torres, Z. [2 ]
Law, A. W. [3 ]
Sato, R. [4 ]
机构
[1] Pfizer SLU, Av Europa 20B, Madrid 28108, Spain
[2] P95 Epidemiol & Pharmacovigilance, Leuven, Belgium
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Inc, Collegeville, PA USA
关键词
Respiratory syncytial virus; Influenza; RSV; Hospitalization; Spain; Cost; BURDEN;
D O I
10.1016/j.vaccine.2024.126683
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Respiratory syncytial virus (RSV) is increasingly a recognized cause of severe respiratory infection among adults. This retrospective observational study compared the costs of RSV and influenza hospitalizations in adults aged >18 years admitted to the Spanish National Healthcare System between 2016 and 2019. Mean costs per hospitalization episode were compared using a multivariable log-gamma generalized linear model adjusted by age, risk group and calendar year. Total annual hospitalization costs were estimated from population incidence rates (for RSV we used model-based rates reported in a published study due to the substantial under-ascertainment of cases) and the mean cost per episode. ICD-10 codes identified a total of 11,662 adults hospitalized with RSV and 79,319 with influenza. The mean length of stay was longer for RSV than for influenza in low-risk patients aged 60-79 years, moderate-risk patients (those with chronic medical conditions) aged >50 years and in high-risk (those with immunocompromising conditions) patients aged <80 years. There were no differences in intensive care unit (ICU) admission (except for higher admission in high-risk RSV patients aged 70-79 years), ICU stay or in-hospital case fatality rate. Mean costs per hospitalization episode were also similar: RSV <euro>3870 (95 % CI 3773-3942) vs influenza <euro>3888 (95 % CI 3836-3931). Total annual costs for RSV-attributable hospitalizations were estimated at M<euro>194, twice than that of influenza (M<euro>83). Annual costs increased by 11 % over the study period for RSV and by 47 % for influenza. In 2019, adults aged >60 years and > 70 years contributed 91 % and 82 %, respectively, of the total RSV-attributable hospitalization costs in adults. RSV has a significant economic burden to the Spanish National Healthcare System, likely greater than influenza. Efficacious RSV vaccines and antivirals have the potential for high public health impact.
引用
收藏
页数:7
相关论文
共 40 条
  • [1] Cost of Hospitalization Associated With Respiratory Syncytial Virus Infection Versus Influenza Infection in Hospitalized Older Adults
    Ackerson, Bradley
    An, Jaejin
    Sy, Lina S.
    Solano, Zendi
    Slezak, Jeff
    Tseng, Hung-Fu
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (06) : 962 - 966
  • [2] Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults
    Ackerson, Bradley
    Tseng, Hung Fu
    Sy, Lina S.
    Solano, Zendi
    Slezak, Jeff
    Luo, Yi
    Fischetti, Christine A.
    Shinde, Vivek
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 69 (02) : 197 - 203
  • [3] [Anonymous], 2011, INSTITUTO NACL ESTAD
  • [4] Morbidity and mortality of respiratory syncytial virus infection in hospitalized adults: Comparison with seasonal influenza
    Atamna, Alaa
    Babich, Tanya
    Froimovici, Dafi
    Yahav, Dafna
    Sorek, Nadav
    Ben-Zvi, Haim
    Leibovici, Leonard
    Bishara, Jihad
    Avni, Tomer
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 103 : 489 - 493
  • [5] Clinical characteristics and population-based attack rates of respiratory syncytial virus versus influenza hospitalizations among adults-An observational study
    Auvinen, Raija
    Syrjanen, Ritva
    Ollgren, Jukka
    Nohynek, Hanna
    Skogberg, Kirsi
    [J]. INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2022, 16 (02) : 276 - 288
  • [6] Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020
    Branche, Angela R.
    Saiman, Lisa
    Walsh, Edward E.
    Falsey, Ann R.
    Sieling, William D.
    Greendyke, William
    Peterson, Derick R.
    Vargas, Celibell Y.
    Phillips, Matthew
    Finelli, Lyn
    [J]. CLINICAL INFECTIOUS DISEASES, 2022, 74 (06) : 1004 - 1011
  • [7] Going Viral-RSV as the Neglected Adult Respiratory Virus
    Busack, Bethany
    Shorr, Andrew F.
    [J]. PATHOGENS, 2022, 11 (11):
  • [8] Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance
    Cai, Wei
    Tolksdorf, Kristin
    Hirve, Siddhivinayak
    Schuler, Ekkehard
    Zhang, Wenqing
    Haas, Walter
    Buda, Silke
    [J]. INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2020, 14 (06) : 630 - 637
  • [9] Clinical outcomes of adults hospitalized for laboratory confirmed respiratory syncytial virus or influenza virus infection
    Chorazka, Magdalena
    Flury, Domenica
    Herzog, Kathrin
    Albrich, Werner C.
    Vuichard-Gysin, Danielle
    [J]. PLOS ONE, 2021, 16 (07):
  • [10] The economic burden of influenza among adults aged 18 to 64: A systematic literature review
    de Courville, Caroline
    Cadarette, Sarah M.
    Wissinger, Erika
    Alvarez, Fabian P.
    [J]. INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2022, 16 (03) : 376 - 385